Business Description
CARISMA Therapeutics Inc
NAICS : 325412
SIC : 2834
ISIN : US14216R1014
Total Employee Number:
46Description
CARISMA Therapeutics Inc is a clinical-stage cell therapy company focused on utilizing Carisma's proprietary chimeric antigen receptor macrophage and monocyte cell engineering platform to develop transformative immunotherapies to treat cancer and other serious diseases. The company has created a comprehensive cell therapy platform to enable the therapeutic use of engineered macrophages and monocytes, which belong to a subgroup of white blood cells called myeloid cells.
Financial Strength
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 3.64 | |||||
Equity-to-Asset | -0.13 | |||||
Debt-to-Equity | -0.88 | |||||
Debt-to-EBITDA | 0.06 | |||||
Interest Coverage | N/A |
N/A
|
N/A
| |||
Piotroski F-Score | 3/9 | |||||
Altman Z-Score | -47.86 | |||||
Beneish M-Score | 21.52 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | -12.5 | |||||
3-Year EPS without NRI Growth Rate | -13 | |||||
3-Year FCF Growth Rate | -14.1 | |||||
3-Year Book Growth Rate | 34.6 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | 32.17 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 37.53 | |||||
9-Day RSI | 45.63 | |||||
14-Day RSI | 47.85 | |||||
3-1 Month Momentum % | -99.71 | |||||
6-1 Month Momentum % | -99.77 | |||||
12-1 Month Momentum % | -99.98 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 0.86 | |||||
Quick Ratio | 0.86 | |||||
Cash Ratio | 0.41 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -1.2 | |||||
Shareholder Yield % | 1100.59 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Operating Margin % | 20.61 | |||||
Net Margin % | 15.28 | |||||
EBITDA Margin % | 23.14 | |||||
FCF Margin % | -42.59 | |||||
OCF Margin % | -42.59 | |||||
ROE % | Neg. Equity | |||||
ROA % | 40.2 | |||||
ROIC % | 118.71 | |||||
3-Year ROIIC % | -186.33 | |||||
ROC (Joel Greenblatt) % | 309.24 | |||||
ROCE % | 114.87 | |||||
Moat Score | 3 | |||||
Tariff Resilience Score | 6 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PE Ratio | 0.03 | |||||
PE Ratio without NRI | 0.02 | |||||
PS Ratio | 0.01 | |||||
EV-to-EBIT | -0.16 | |||||
EV-to-EBITDA | -0.14 | |||||
EV-to-Revenue | -0.03 | |||||
EV-to-Forward-Revenue | 0.73 | |||||
EV-to-FCF | 0.08 | |||||
Earnings Yield (Greenblatt) % | -625 | |||||
FCF Yield % | -8755.86 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with OTCPK:CARM
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
CARISMA Therapeutics Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 52.632 | ||
| EPS (TTM) ($) | 0.2 | ||
| Beta | 0.9973 | ||
| 3-Year Sharpe Ratio | -1.25 | ||
| 3-Year Sortino Ratio | -1.43 | ||
| Volatility % | 5931.53 | ||
| 14-Day RSI | 47.85 | ||
| 14-Day ATR ($) | 0.005489 | ||
| 20-Day SMA ($) | 0.009068 | ||
| 12-1 Month Momentum % | -99.98 | ||
| 52-Week Range ($) | 0.0001 - 0.556 | ||
| Shares Outstanding (Mil) | 41.85 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
CARISMA Therapeutics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
CARISMA Therapeutics Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Third quarter earnings results for 2026 | 2026-11-12 | In 132 days | ||
| Second quarter earnings results for 2026 | 2026-08-07 | In 35 days | ||
| First quarter earnings results for 2026 | 2026-07-14 | In 11 days | ||
| General meeting for 2025 | 2026-07-08 | In 5 days | ||
| Third quarter earnings results for 2025 | 2025-11-12 | 0.05 (+2.34%) | ||
| Second quarter earnings results for 2025 | 2025-08-07 | 0.31 (-2.93%) | ||
| First quarter earnings results for 2025 | 2025-05-13 | 0.19 (-3.36%) | ||
| Annual report for 2024 | 2025-03-31 | 0.33 (-7.82%) | ||
| H.C. Wainwright 3rd Annual Cell Therapy Virtual Conference | 2025-02-25 10:30 | 0.44 (-3.91%) | ||
| Oppenheimer 35th Annual Healthcare Life Sciences Conference | 2025-02-11 16:40 | 0.44 (-2.62%) |
Show
Entries
CARISMA Therapeutics Inc Frequently Asked Questions
What is CARISMA Therapeutics Inc(CARM)'s stock price today?
The current price of CARM is $0.01. The 52 week high of CARM is $0.56 and 52 week low is $0.00.
When is next earnings date of CARISMA Therapeutics Inc(CARM)?
The next earnings date of CARISMA Therapeutics Inc(CARM) is 2026-07-14 Est..
Does CARISMA Therapeutics Inc(CARM) pay dividends? If so, how much?
CARISMA Therapeutics Inc(CARM) does not pay dividend.
Guru Commentaries on OTCPK:CARM
No articles.
Press Release
Articles on CARISMA Therapeutics Inc
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers